Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
暂无分享,去创建一个
S. Solomon | R. Diaz | J. McMurray | G. Felker | M. Metra | B. Claggett | J. Fang | J. Howlett | E. O'meara | S. Heitner | D. Bonderman | Siddique A Abbasi | J. Teerlink | C. Fonseca | M. Pagnesi | S. Abbasi | F. Malik | Stuart Kupfer | Jing Li | E. Goncalvesova | Zi Michael Miao | S. Kupfer | E. O’Meara | Z. M. Miao | M. Pagnesi | Generosa Crespo-Leiro
[1] Akshay S. Desai,et al. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial , 2016, Circulation. Heart failure.
[2] D. Mozaffarian,et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.
[3] P. Ponikowski,et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.
[4] Jose H. Flores-Arredondo,et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. , 2021, Journal of the American College of Cardiology.
[5] K. Anstrom,et al. Clinical factors related to morbidity and mortality in high‐risk heart failure patients: the GUIDE‐IT predictive model and risk score , 2019, European journal of heart failure.
[6] D. DeMets,et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) , 2020, European heart journal.
[7] M. Metra,et al. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? , 2021, European heart journal. Cardiovascular pharmacotherapy.
[8] P. Ponikowski,et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials , 2020, European journal of heart failure.
[9] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[10] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[11] D. Cox,et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.
[12] A. Cohen-Solal,et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients , 2020, European journal of heart failure.
[13] J. Ferreira. Omecamtiv Mecarbil: a Personalized Treatment for Patients with Severely Impaired Ejection Fraction. , 2021, Journal of the American College of Cardiology.
[14] J. Rouleau,et al. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? , 2020, JACC. Heart failure.
[15] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[16] J. Rouleau,et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.
[17] Roberto Ferrari,et al. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.
[18] V. J. Planelles-Herrero,et al. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil , 2017, Nature Communications.
[19] R. McKelvie,et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. , 2021, The Canadian journal of cardiology.
[20] S. Solomon,et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.
[21] S. Solomon,et al. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. , 2020, JACC. Heart failure.
[22] G. Parati,et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison , 2017, European journal of heart failure.
[23] S. Solomon,et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics , 2021, European journal of heart failure.
[24] J. H. Patterson,et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.
[25] R. Wachter,et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up‐titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study , 2018, European journal of heart failure.
[26] G. Fonarow,et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.
[27] J. Teerlink,et al. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction. , 2017, Handbook of experimental pharmacology.